Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application
pharmaceutical investing scPharmaceuticals Receives Complete Response Letter from the FDA for FUROSCIX
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR